A “breakthrough” new three-drug combination offers hope for women battling an aggressive form of breast cancer, potentially ...

Discover how breast cancer precision oncology using a combination therapy improves survival in advanced PIK3CA-mutated cases.

CHICAGO -- Adding the PI3K-pathway inhibitor inavolisib (Itovebi) to palbociclib (Ibrance) and fulvestrant significantly improved survival in advanced breast cancer patients with PIK3CA-mutated, ...

INAVO120 trial shows inavolisib, palbociclib, and fulvestrant significantly improved overall survival in PIK3CA-mutant advanced breast cancer.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive final results from the overall ...

A new triple-drug treatment for aggressive advanced breast cancer can cut deaths by a third, a major trial has found.

SAN ANTONIO -- The addition of palbociclib (Ibrance) to current standard-of-care therapy following induction chemotherapy resulted in a significant and clinically meaningful improvement in ...

The phase 3 PADMA trial demonstrated that first-line treatment with palbociclib plus endocrine therapy (ET) significantly improves outcomes compared with standard mono chemotherapy in patients ...

The lead author said the study also showed the inavolisib-based therapy "more than doubled the time before their cancer progressed or worsened".

The addition of palbociclib to anti-HER2 and endocrine therapy extended PFS by more than a year. The regimen appeared well tolerated, according to investigators. Perspective from Antoinette R.

A recently completed phase 3 clinical trial, conducted by researchers at Mass General Brigham and collaborators, shows that combining inavolisib with palbociclib and fulvestrant improves overall ...